Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Here's Why

Key Points

• Genmab A/S shares opened at $232.30 after closing at $216.31, indicating a significant gap up in price.
• The company's recent earnings report showed an earnings per share (EPS) of $5.42, which exceeded analysts' expectations of $3.99.
• Genmab A/S has a market cap of $15.35 billion and a net margin of 37.53% from its latest quarter's revenue of $925 million.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $216.31, but opened at $232.30. Genmab A/S shares last traded at $232.30, with a volume of 17 shares traded.

Genmab A/S Price Performance

The stock's 50-day moving average is $215.56 and its 200-day moving average is $206.96. The stock has a market cap of $15.35 billion, a price-to-earnings ratio of 11.66 and a beta of 0.93.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.99 by $1.43. The firm had revenue of $925.00 million for the quarter, compared to analyst estimates of $949.06 million. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.